Table 4.
Efficacy of COVID-19 vaccines in real word.
| Vaccine | Country | No. of participants | Age | Efficacy (%) (95%CI) | Ref | |||
|---|---|---|---|---|---|---|---|---|
| prevention of Covid-19 | prevention of hospital | prevention of severe disease | prevention of death | |||||
| CoronaVac | Chile | 10,187,720 | ≥16 | 65.9 (65.2- 66.6) | 87.5 (86.7-88.2) | 90.3 (89.1-91.4) | 86.3 (84.5- 87.9) | (26) |
| BNT162b2, mRNA-1273 | Canada | 324 033 | ≥16 | 91 (89- 93) | 98 (88- 100) (hospital or death) | (99) | ||
| BNT162b2 | Israel | 119,236 | ≥16 | 92 (88- 95) | 87 (55-100) | 92 (75- 100) | – | (100) |
| BNT162b2 | Qatar | – | – | – | – | 97.4 (92.2- 99.5) | (101) | |
| BNT162b2* | Unite States | 51,738 | ≥18 | 76 (69-81) | 85 (73-93) | – | – | (102) |
| mRNA-1273* | Unite States | 51,738 | ≥18 | 86 (81-90.6) | 91. (81-97) | – | – | (102) |
*Alpha or Delta variant was highly prevalent in this region in this study.